Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 4,119 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Central Abdominal Bulging
Interventions: LIPO-202, Placebo; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 6
States / cities: Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more

Conditions: Epistaxis
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Mercy Health Ohio; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boardman, Ohio • Youngstown, Ohio

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more

Conditions: Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: AZD8853, Zirconium-89 crefmirlimab berdoxam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions: YG1699, Dapagliflozin; Drug
Lead sponsor: Youngene Therapeutics Inc., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Malaria, Falciparum
Interventions: FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 4,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Sheffield, Alabama • Northridge, California • Cutler Bay, Florida + 9 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device; Combination Product · Drug · Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Humble, Texas

Conditions: Advanced Solid Tumors, Advanced B-cell NHL
Interventions: Urelumab, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 11
States / cities: Palo Alto, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Healthy
Interventions: LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS); Biological · Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: HIV
Interventions: FAmily-CEntered Advance Care Planning, Healthy Living Control; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Washington D.C., District of Columbia

Conditions: Domestic Violence
Interventions: two day skills group plus treatment adjuncts, two day skills group control group; Behavioral
Lead sponsor: Rory Newlands; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Breast Cancer
Interventions: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Sleep Apnea, Rhinosinusitis Chronic
Interventions: Dupilumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Arthroplasty
Interventions: Prophylactic Antibiotics, Control Antibiotics; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Organ Transplantation
Interventions: Belatacept, Sirolimus, Alemtuzumab; Drug
Lead sponsor: Allan D Kirk, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Experimental: Pharmacist-Bidirectional Texting Group, Active Comparator: Control Group; Other
Lead sponsor: Linnea Polgreen; Other
Eligibility: 21 Years to 100 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Muscular Atrophy, Spinal
Interventions: risdiplam, omeprazole; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Cancer
Interventions: FAmily CEntered Advance Care Planning for Teens with Cancer; Behavioral
Lead sponsor: Maureen Lyon; Other
Eligibility: 14 Years to 99 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Minneapolis, Minnesota • Akron, Ohio + 1 more

Conditions: Sleep Disturbance
Interventions: High Touch intervention, Medium Touch intervention, Low Touch intervention, Sleep Education Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Intranasal TXA for Anterior Epistaxis in the Emergency Department

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

A Study of Two Formulations of LY3074828 in Healthy Participants

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care

Evaluating the Clinical Utility and Client Acceptability of Video Intervention

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis

Effect of Prophylactic Antibiotics on Intra-Operative Culture Results

Belatacept Post Depletional Repopulation to Facilitate Tolerance

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer

Calm Sleep Coaching